Skip to search formSkip to main contentSkip to account menu

Revlimid

Known as: Celgene brand of lenalidomide, Revimid 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

lenalidomide
lenalidomide 15 MG Oral Capsule [Revlimid]lenalidomide 25 MG Oral Capsule [Revlimid]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
Objective: To evaluate a novel functional composite endpoint (CEP) based on disability progression and cognitive processing speed… 
2019
2019
Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006)
Objective: To explore the relationship between plasma neurofilament light chain (NfL) levels and relapsing multiple sclerosis… 
2017
2017
Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
7556Background: Currently there is no optimal salvage regimen for relapsed/refractory NHL (R/R NHL). Prognosis of pts who fail to… 
Review
2015
Review
2015
OP0276 Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review…
Background Large pivotal randomised controlled trials (RCTs) in rheumatoid arthritis (RA) increasingly employ “adaptive” designs… 
2014
2014
Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3
Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow is Associated to Longer Survival in Newly Diagnosed Myeloma… 
Review
2011
Review
2011
A 71-year-old woman with multiple myeloma status after stem cell transplantation.
A 71-year-old woman with a 9-year history of monoclonal gammopathy of undetermined significance presented with anemia [hemoglobin… 
2008
2008
Effect of bortezomib, cyclophosphamide, and filgrastim on complete remission rates and CD34+ stem cell collections in multiple myeloma (MM)
8587 Background: Typical stem cell mobilization regimens in MM include G-CSF alone or with high-dose cyclophosphamide. Given the… 
2006
2006
Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.
Lenolidamide (Revlimid®) is an oral immunomodulatory drug that has been shown to be effective for the treatment of relapsed… 
Review
2005
Review
2005
Cure of myeloma: hype or reality?
Summary:High-dose treatment (HDT) with autologous stem cell transplant(s) (ASCT) improved survival, when compared to standard… 
2005
2005
Trasplante de células hematopoyéticas en mieloma múltiple
Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients per year in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)